UNSPSC 51331902: Lithium citrate

This classification denotes an antipsychotic agent with the molecular formula C6H5O7.3Li.4H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z6E9K79YV, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, trilithium salt but generally known as lithium citrate, which bears US NIH Compound Identifier 13520. European Medicines Agency schedules Lithium citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14377MIG. Most nations schedule lithium citrate under HS 29181590 and SITC 51391.

As of Q4 2014, LITHIUM CITRATE remains the US FDA Preferred Term for this commodity. Lithium citrate bears US NLM identifiers UMLS ID C0125997 and NCI Concept Code C61812. SMILES: OC(CC(=O)O)(CC(=O)O)C(=O)O.[LI].[LI].[LI].

UNSPSC 51331902 Lithium citrate (Commodity) shows minimal direct alignment with recent state and local procurement activity. The code nominally covers a specific pharmaceutical compound used in psychiatric treatment, yet the three most recent opportunities posted under this code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products across a cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations reference lithium citrate or psychiatric pharmaceuticals. The mismatch suggests either improper code tagging in the source data or that state and local procurement offices are applying this Commodity code to broader pharmaceutical procurement categories rather than the specific product line it nominally describes.

The geographic spread of recent activity spans Florida, Texas, and Minnesota, with the Minnesota opportunity serving multiple participating jurisdictions through cooperative purchasing. Issuing bodies include county governments (Seminole County), state health agencies (Texas HHS), and state procurement offices administering cooperative agreements (Minnesota Department of Administration). The representative solicitations are an IFB from Seminole County posted June 30, 2026, with a July 26, 2023 response deadline for naloxone and drug deactivation systems; an RFI from Texas HHS posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer pharmacy programs; and an RFP from MMCAP posted January 20, 2026, with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products. Given the code's nominal scope does not match the work actually being solicited, the category presents limited opportunity relevance for vendors specializing in lithium citrate or psychiatric pharmaceutical products.